Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report) insider Howard Lazarus sold 13,300 shares of the stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $27.90, for a total value of $371,070.00. Following the completion of the transaction, the insider owned 13,300 shares of the company’s stock, valued at $371,070. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Avalyn Pharma Trading Down 1.0%
NASDAQ AVLN opened at $28.40 on Friday. The firm has a market capitalization of $1.26 billion and a PE ratio of -1.21. The business’s 50-day moving average price is $27.93 and its two-hundred day moving average price is $29.87. The company has a current ratio of 25.76, a quick ratio of 25.76 and a debt-to-equity ratio of 0.04. Avalyn Pharma Inc. has a 12 month low of $22.24 and a 12 month high of $40.17.
Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.03). On average, analysts expect that Avalyn Pharma Inc. will post -3.87 EPS for the current year.
Hedge Funds Weigh In On Avalyn Pharma
A number of large investors have recently made changes to their positions in the stock. Algert Global LLC bought a new stake in shares of Avalyn Pharma during the third quarter valued at about $465,000. Soleus Capital Management L.P. lifted its holdings in shares of Avalyn Pharma by 143.2% during the 3rd quarter. Soleus Capital Management L.P. now owns 1,019,000 shares of the company’s stock worth $29,031,000 after acquiring an additional 600,000 shares during the last quarter. State Street Corp lifted its stake in Avalyn Pharma by 73.7% during the third quarter. State Street Corp now owns 554,004 shares of the company’s stock worth $15,784,000 after purchasing an additional 235,009 shares during the last quarter. Profund Advisors LLC purchased a new stake in Avalyn Pharma in the third quarter worth approximately $668,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Avalyn Pharma during the 3rd quarter valued at $29,000.
Analysts Set New Price Targets
AVLN has been the subject of several recent research reports. Morgan Stanley decreased their target price on shares of Avalyn Pharma from $57.00 to $53.00 and set an “overweight” rating for the company in a research report on Monday, November 16th. Wall Street Zen upgraded Avalyn Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 14th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Avalyn Pharma in a research report on Wednesday, November 11th. Finally, Raymond James Financial assumed coverage on Avalyn Pharma in a research report on Friday, October 2nd. They set an “outperform” rating and a $60.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $59.20.
Get Our Latest Report on Avalyn Pharma
About Avalyn Pharma
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.
Further Reading
- Five stocks we like better than Avalyn Pharma
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
